STATISTICALLY OPTIMIZED AND BOX-BEHNKEN DESIGN ASSISTED METHOD DEVELOPMENT AND VALIDATION OF AN ANTIPSYCHOTIC MEDICATION OLANZAPINE AND ITS RELATED IMPURITIES BY REVERSE-PHASE HPLC-UV SPECTROSCOPY
Keywords:Olanzapine, Forced degradation, Box-Behnken design, Experimental design, HPLC-UV
Objective: Statistically designed and Box-Behnken design (BBD) assisted reversed-phase high-performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated for the identification of an antipsychotic medication Olanzapine and its organic impurities in pure drug along with forced degradation studies.
Methods: The present developed method employed BBD optimized chromatographic conditions comprising of an Inertsil ODS 3V analytical column with dimension 250 mm x 4.6 mm and particle size 5µ. The isocratic mobile phase was used as a mixture of monobasic sodium phosphate buffer (0.01 M, pH 6), methanol and acetonitrile in the proportion of 40/30/30, v/v. The mobile phase flow rate and UV λmax was 1 ml/min and 260 nm, respectively. The method was optimized by Box-Behnken design using design expert software, comprising of three factors for Olanzapine for instance flow rate (A), mobile phase composition (B) and pH (C) while resolution between Olanzapine related compound A and Olanzapine related compound B (Y1) and tailing of Olanzapine (Y2) were taken as a response.
Results: Application of BBD yielded statistically designed method with excellent quality parameters achieved in terms of linearity with the coefficient of correlation (R2>0.9999), limit of detection (LOD, 0.0023-0.16 µg/ml), the limit of quantification (LOQ, 0.007-0.39 µg/ml), accuracy (99-100%) and precision ((2%, relative standard deviation (%RSD) were evaluated as per latest available procedures.
Conclusion: Forced degradation conditions were carried out, demonstrated that the optimized method was stable and no any interfering peaks eluting at the similar retention time of the studied compounds. The method was found to be stable, easy, rugged and robust, could be applied for the similar types of the pure drug.
Revanasiddappa H, Deepakumari H. Highly sensitive spectrophotometric method for the quantitative determination of olanzapine in its pure and in pharmaceutical dosage forms. J Sci Indus Res 2014;73:41–105.
Raggi M, Casamenti C, Mandrioli R, Fanali S, De Ronchi D, Volterra V. Determination of the novel antipsychotic drug olanzapine in human plasma using HPLC with amperometric detection. Chromatographia 2000;51:562–6.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
Bhana N, Perry CM. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs 2001;15:871-904.
Pradhan K, Mishra U, Pattnaik S, Panda C, Sahu K. Development and validation of a stability-indicating UV spectroscopic method for candesartan in bulk and formulations. Indian J Pharm Sci 2014;6:67-72.
Basavaiah K, Abdulrahman SA. Sensitive and selective methods for the determination of olanzapine in pharmaceuticals using N-bromosuccinimide and two dyes. Int J Chem Tech Res 2010;2:660–8.
Krebs A, Starczewska B, Puzanowska Tarasiewicz H, Sledz J. Spectrophotometric de termination of olanzapine by its oxidation with N-bromosuccinimide and cerium (IV) sulfate. Anal Sci 2006;22:829–33.
Cui D, Li Y, Lian M, Yang F, Meng Q. Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. Analyst 2011;136:3149-56.
D'Arrigo C, Migliardi G, Santoro V, E Spina E. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2006;28:388–93.
Murthy AR, Babu KR, Vekariya N. Analytical method development and validation of olanzapine by high-performance liquid chromatography. Int J Pharm Sci Drug Res 2015;7:188-92.
Rao RN, Raju AN, Narsimha R, Babu GR. Isolation and characterization of process-related impurities of olanzapine using HPLC and ESI‐MS/MS. J Sep Sci 2008;301:107-18.
Niedermeier S, Scriba GK. A quality by design-based approach to a capillary electrokinetic assay for the determination of dextromepromazine and levomepromazine sulfoxide as impurities of levomepromazine. J Pharm Biomed Anal 2017;146:402-9.
Peraman R, Bhadraya Padmanabha YR. Analytical quality by design: a tool for regulatory flexibility and robust analytics. Int J Anal Chem 2015;2015:1-9.
Khanam N, Alam MI, Ali Y, Siddiqui AR. A review on optimization of drug delivery system with experimental designs. Int J Appl Pharm 2018;10:7-12.
Alam MI, Siddiqui AR, Khanam N, Kamaruddin SJ. A multivariate quantification of box-behnken design assisted method development and validation of dextromethorphan hydrobromide and desloratadine simultaneously by reverse-phase HPLC in in-house syrup formulation. J Sep Sci 2020;43:1-10.
Tome T, Zigart N, Casar Z, Obreza A. Development and optimization of liquid chromatography analytical methods by using AQbD principles: overview and recent advances. Organic Process Res Dev 2019;23:1784-802.
Alam I, Khanam N, Shaikh JK, Ganguly S. Quality by design-a recent trend in pharmaceutical industries. World J Pharm Res 2016;5:608-20.
Tumpa, Stajic A, Jancic Stojanovic B, Medenica M. Quality by design in the development of hydrophilic interaction liquid chromatography method with gradient elution for the analysis of olanzapine. J Pharm Biomed Anal 2017;134:18-26.
Reddy BA, Alam MI, Khanam N, Krishnanand PR. An innovative method development and forced degradation studies for simultaneous estimation of sofosbuvir and ledipasvir by RP HPLC. Int J Pharm Pharm Sci 2019;11:34-41.
Naazneen S, Sridevi A. Development of assay method and forced degradation study of valsartan and sacubitril by RP-HPLC in tablet formulation. Int J Appl Pharm 2017;9:9-15.